Collaboration with noted neurologists to plan next clinical studies

May 11, 2009

By Flinn Foundation

[Source: PRNewswire-FirstCall] – Transgenomic, Inc. (OTCBulletinBoard: TBIO) and Power3 Medical Products, Inc. (OTCBulletinBoard: PWRM) , announced the clinical introduction of the NuroPro(R) AD and NuroPro(R) PD tests for Alzheimer’s and Parkinson’s disease at the 2009 American Academy of Neurology meeting in Seattle, WA. The NuroPro tests help clinicians distinguish patients with Alzheimer’s and Parkinson’s diseases from “normal” individuals and patients with other neurological disorders. The tests, developed by Power3, are a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has neurodegenerative disease. This information will help physicians make earlier diagnoses and recommend appropriate follow-up and treatment options for their patients.

For more information click here.